Jay R. Luly, Ph.D., is the President and Chief Executive Officer at Enanta Pharmaceuticals Inc., a position he has held since the company's inception. Dr. Luly is a distinguished scientist and business leader with a robust background in the biopharmaceutical industry. He earned his Ph.D. in Organic Chemistry from the California Institute of Technology and began his career at Abbott Laboratories, where he played a pivotal role in the discovery and development of the HIV protease inhibitor Norvir, which has been a critical component in the treatment of HIV/AIDS. Before founding Enanta Pharmaceuticals in 1995, Dr. Luly held significant positions at Abbott Laboratories, rising to the level of Divisional Vice President of Pharmaceutical Research and Development. His leadership and scientific expertise were instrumental in guiding Enanta's focus on the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Under his stewardship, Enanta has achieved notable success, including the development of MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), a leading treatment for chronic hepatitis C virus (HCV) infection that has transformed the landscape of hepatitis C treatment. As President and CEO, Dr. Luly continues to steer Enanta towards new frontiers in drug discovery, emphasizing innovative research and strategic collaborations. His vision has positioned Enanta as a leader in the development of novel therapies for respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), and other serious diseases. Dr. Luly's commitment to advancing medical science and his strategic leadership have been crucial to Enanta's growth and success, making him a respected figure in the biopharmaceutical industry.